Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/45759
Title: Cost-Effectiveness Analysis of Renin-Angiotensin Aldosterone System Blockade in Progression of Chronic Kidney Disease
Authors: Oraluck Pattanaprateep
Atiporn Ingsathit
Mark McEvoy
John Attia
Ammarin Thakkinstian
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
University of Newcastle, Australia
Hunter Medical Research Institute New Lambton Heights
Keywords: Economics, Econometrics and Finance;Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-May-2018
Citation: Value in Health Regional Issues. Vol.15, (2018), 155-160
Abstract: © 2018 Objectives: To assess the cost effectiveness of renin-angiotensin aldosterone system (RAAS) blockade in the progression of chronic kidney disease using Thai clinical data in 2014. Methods: A Markov model for cost-effectiveness analysis was applied to estimate from a societal perspective the cost per quality-adjusted life-year (QALY) gained and the incremental cost-effectiveness ratio of RAAS versus non-RAAS used in preventing the progression of end-stage renal disease and death stratified by diabetic and nondiabetic patients. Input parameters related to clinical outcomes were obtained from a cohort study of treatment effectiveness, whereas costs were retrieved from the Ramathibodi Hospital electronic database in 2015 and the Health Intervention and Technology Assessment Program in Thailand. One-way analysis and probabilistic sensitivity analysis were performed to evaluate uncertainty surrounding model parameters. Results: From the model, using RAAS improved QALY from 2.41 to 3.16 years and from 2.37 to 3.20 years in diabetic and nondiabetic groups, respectively. The incremental cost-effectiveness ratios for these groups were 78,250 baht (US $2,353.39) and 66,674 baht (US $2,005.22), respectively. Conclusions: Using RAAS in patients with chronic kidney disease improved QALY in both diabetic and nondiabetic patients and proved to be cost-effective.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046802610&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/45759
ISSN: 22121102
22121099
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.